Group 1 - Multiple real estate companies are accelerating debt restructuring, with diverse debt solutions being implemented [7] - The total debt due for real estate companies in 2025 is projected to reach 525.7 billion yuan, an increase of approximately 8.9% from 2024 [7] - Companies like Kaisa Group, Sunac China, and Country Garden have announced their latest debt restructuring progress [7] Group 2 - The National Bureau of Statistics reported a 0.1% year-on-year decline in consumer prices in May, with urban prices remaining stable and rural prices decreasing by 0.4% [3] - The Producer Price Index (PPI) fell by 0.4% month-on-month and 3.3% year-on-year in May, with the decline attributed to international input factors and domestic energy price decreases [4] Group 3 - Starbucks China announced a collective price adjustment for dozens of products, with an average price drop of 5 yuan for large cups [26] - The company aims to enhance its non-coffee beverage market presence [26] Group 4 - The China Securities Regulatory Commission imposed fines totaling 1.6624 billion yuan on Dongxu Optoelectronics for information disclosure violations and fraudulent issuance [11] - The company and its executives received various penalties, including lifetime bans from the securities market [11] Group 5 - The Ministry of Industry and Information Technology emphasized increased inspections on vehicles with significant quality and safety concerns [37] - The agency aims to ensure compliance with national standards and manage production consistency [37]

Group 1 - The company, BrightGene Bio-Medical Technology Co., Ltd., issued convertible bonds totaling RMB 465 million, with a net fundraising amount of RMB 456.83 million after deducting issuance costs [3][18]. - The bonds have a maturity period of six years, from January 4, 2022, to January 3, 2028, with a face value of RMB 100 per bond [3][4]. - The coupon rates for the bonds are structured to increase over the years, starting at 0.4% in the first year and reaching 3% in the sixth year [3][4]. Group 2 - The company reported a revenue of RMB 1.28 billion for the fiscal year 2024, representing an 8.74% increase from the previous year [17]. - The net profit attributable to shareholders decreased by 3.12% to RMB 180.51 million, primarily due to increased R&D expenses [17]. - The company’s total assets increased by 2.63% to RMB 5.16 billion, indicating stable growth in its financial position [17]. Group 3 - The company focuses on innovative pharmaceutical development, emphasizing original drugs and complex formulations to meet unmet clinical needs globally [15][16]. - Key therapeutic areas include antiviral, antifungal, immunosuppressive, respiratory, oncology, and metabolic diseases, with core products in each category [16]. - The company has a strong commitment to R&D, with R&D expenses increasing by 19.65% year-on-year, reflecting its strategy of being research-driven [17]. Group 4 - The bonds are rated AA- by Dongfang Jincheng International Credit Rating Co., Ltd., with a stable outlook, indicating a strong credit profile [5][21]. - The company has established a dedicated fund management system to ensure the proper use of raised funds, adhering to regulatory requirements [20]. - The company has not experienced any defaults on bond repayments, demonstrating a stable repayment capability [21].

中办、国办：完善最低工资标准调整机制，合理提高最低工资标准 中共中央办公厅、国务院办公厅印发《关于进一步保障和改善民生 着力解决群众急难愁盼的意见》，其中提 出，加强低收入群体兜底帮扶。充分运用大数据比对与实地摸排相结合等方式，加强动态监测预警，及时将符 合条件的群众纳入社会救助范围。制定低收入人口认定办法、低收入家庭经济状况核对办法，全面开展低保边 缘家庭、刚性支出困难家庭认定。合理确定调整最低生活保障标准，与城乡居民人均消费支出相挂钩，切实保 障困难群众基本生活。加强最低生活保障标准与其他社会救助标准的统筹衔接。完善最低工资标准调整机制， 合理提高最低工资标准。制定技能人才最低工资分类参考指引。实施农村低收入人口开发式帮扶提能增收行 动，建立农村低收入家庭劳动力劳动伤害帮扶机制。加大以工代赈实施力度，优先吸纳带动低收入人口就地就 近就业增收。 外交部回应中美经贸磋商 据央视新闻，外交部例行记者会上，针对中美高官今天在伦敦会面的提问，外交部发言人林剑表示，中方已经 发布了中美经贸磋商机制首次会议有关消息，关于磋商的具体情况请保持关注。 AI+"苏超"！江苏苏州拟征集"人工智能+"技术，助力备战省城市足球联赛 ...

Summary of Key Points Core Viewpoint - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has successfully completed its initial public offering (IPO) of 25.7 million shares, with the shares set to be listed on the Shenzhen Stock Exchange on December 11, 2024. The total share capital post-IPO will be 102.8 million shares, with a significant portion subject to trading restrictions [1]. Group 1: IPO and Share Structure - The company received approval from the China Securities Regulatory Commission for its IPO, issuing 25.7 million shares, increasing the total share capital from 77.1 million to 102.8 million shares [1]. - After the IPO, 76.29% of the total shares will be subject to trading restrictions, while 23.71% will be freely tradable [1]. - Following a profit distribution plan approved at the 2024 annual shareholders' meeting, the total share capital will further increase to 133.64 million shares, with 76.29% still under trading restrictions [1]. Group 2: Lock-up Period and Compliance - Under the IPO terms, 10% of the shares allocated to offline investors will be subject to a 6-month lock-up period, while 90% will be tradable immediately upon listing [2]. - All shareholders holding restricted shares have complied with the lock-up commitments, and there are no violations affecting the listing of these shares [2]. Group 3: Changes in Share Capital Structure - The number of restricted shares decreased by 1,724,702 shares, resulting in 100,230,000 restricted shares, which is 75% of the total share capital post-IPO [4]. - The number of unrestricted shares increased to 33,410,000, representing 25% of the total share capital after the release of the lock-up [4]. Group 4: Sponsor's Verification - The sponsor has confirmed that the release of restricted shares complies with relevant regulations and that the company's disclosures regarding the restricted shares are accurate and complete [6].

关注创新药行情全面扩散下的投资机会 证 券 研 究 报 告 2025下半年医药生物行业投资策略 证券分析师：张静含 A0230522080004 2025.6.9 投资案件 一改颓势，医药板块上半年表现亮眼 -15% -10% -5% 0% 5% 10% 15% 20% 25% 2025/01/02 化学制药 生物制品 医疗器械 医药商业 中药 医疗服务 年初至今医药及大盘涨跌幅对比 年初至今医药二级板块涨跌幅对比 -10% -8% -6% -4% -2% 0% 2% 4% 6% 8% 10% 25/01 25/02 25/03 25/04 25/05 25/06 相对全A涨跌幅 医药生物(申万) 万得全A(除金融、石油石化) www.swsresearch.com 证券研究报告 2 ◼ 年初至6/5，医药生物（申万）指数年初至今累计涨跌幅为+8.0%，同期万得全A（除金融石油石化）涨跌幅为 +2.7%，相对大盘涨跌幅为+5.2%，在申万一级行业中排名第5。从二级行业行情表现来看，年初至今涨跌幅排名分 别为：化学制药（35.0x→41.6x）、生物制品（29.8x→41.6x）、医疗器械（30.3x→34.7 ...

金十数据6月9日讯，常山药业6月9日公告，股票连续两个交易日收盘价格涨幅偏离值累计超过30%，根 据深圳证券交易所的相关规定，属于股票交易异常波动的情况。自2025年5月6日至6月9日期间，公司股 价累计涨幅达147.69%，已经严重偏离同行业和创业板综合指数增长幅度。公司艾本那肽注射液用于治 疗2型糖尿病的上市许可申请已经获得国家药监局受理，目前处于专业审评阶段，艾本那肽注射液上市 审评后续环节仍然较多，艾本那肽最终能否获批上市及获批时间仍存在不确定性。公司艾本那肽注射液 拟用于减重适应症的临床试验申请已经获得国家药监局受理，目前处于审评阶段，能否获得临床试验批 准通知书存在不确定性。 常山药业：艾本那肽注射液处于审评阶段，能否获批存在不确定性 ...

一、 复盘点评： 沪指再次站上 3400 ，量能站上 1.3 万亿，科技风偏正在回归 1. 大盘指数走势及成交量强度表现 AI 方向全线异动 ：天孚通信、中际旭创表现强劲， 粤传媒和引力传媒涨停，港股尾盘 AI 应用大涨， 资金持续回补科技主线。 今日 A 股市场整体呈现强势震荡上行格局，沪指上涨 0.43% ， 重新站上 3400 点整数关口，实现 " 五连阳 " ，创业板指表现更为强劲，涨 幅达 1.07% ，反映出市场风险偏好提升。沪深两市成交额达 1.31 万亿元，较前一交易日显著放量超 1350 亿元，放量上涨显示做多资金持 续活跃，量能配合良好，市场动能充沛。 主力资金净流入明显，重点流入方向为医药、新能源、人工智能与国企改革方向。主力净流入个股中，东方财富、中际旭创、恒瑞医药、天孚 通信等龙头表现突出，显示资金更倾向于高景气 + 产业趋势明确 + 技术逻辑支撑的赛道 核心标的 。 | 体育 | | | 文娱用品 | | | 金属新材料 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | - ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Group 1 - Jinling Sports announced that its convertible bonds experienced significant abnormal fluctuations, with a cumulative price deviation of 39.14% over three consecutive trading days, indicating potential irrational trading behavior and high market risk [3] - Haichen Pharmaceutical reported that its solid-state battery-related business has not yet generated revenue, and the project faces risks related to industrialization and commercialization due to macroeconomic and market environment changes [4] - Jinying Co. confirmed that there have been no significant changes in its daily operations, with stable production costs and sales, and no major adjustments in market conditions or industry policies [5] Group 2 - Lingyi Technology received acceptance from the Shenzhen Stock Exchange for its plan to issue convertible bonds and acquire a 66.46% stake in Jiangsu Kedasitern Automotive Technology Co., Ltd., along with raising supporting funds [6] - Sichuan Road and Bridge announced plans to acquire 100% equity of Chengdu Xinzhu Transportation Technology Co., Ltd. and other related assets to enhance its bridge component business and improve market competitiveness [7] Group 3 - Jianghuai Automobile reported May sales of 33,400 vehicles, a year-on-year decrease of 3.52%, with new energy vehicle sales dropping by 57.81% [9] - Aonong Biological announced May sales of 156,200 pigs, a year-on-year increase of 9.44%, with a total stock of 536,400 pigs at the end of May, reflecting a 22.56% year-on-year increase [10] - Juxing Agriculture reported May sales of 328,000 pigs, a significant year-on-year increase of 61.5%, generating sales revenue of 579 million yuan [12] Group 4 - Hongyuan Electronics' controlling shareholders plan to reduce their holdings by up to 1% of the company's total shares due to personal funding needs [14] - Kaichun Co. announced an increase in its share repurchase price limit from 26.625 yuan to 40 yuan per share, effective June 10, 2025 [16]

826只股公布截至5月31日最新股东户数，相比上期股东户数下降的有377只，降幅居前的是哈三联、中 欣氟材、光智科技等。 投资者除了在定期报告中获得股东信息数据外，还可以在交易所互动平台上通过提问方式了解部分公司 更及时（每月10日、20日、月末）的股东户数信息。以往3期分别有731家、670家、657家公司在互动平 台透露了股东户数，截至发稿，共有826家公司公布了截至5月31日股东户数。 上期筹码集中股回测：62%跑赢沪指 证券时报·数据宝对上一期(5月20日)筹码集中股监测显示，这些股5月11日以来平均上涨4.82%，走势强 于同期沪指表现（上涨1.73%），其中，62%的筹码集中股相对大盘获超额收益。 上期股东户数降逾一成个股中，*ST和科涨幅最高，5月11日以来累计上涨31.87%，涨幅居前的还有万 通智控、速达股份等。 27股最新股东户数降逾一成 证券时报·数据宝统计显示，共有826只个股公布了5月31日股东户数，与上期（5月20日）相比，股东户 数下降的有377只。其中股东户数降幅超一成的有27只。 股东户数降幅最多的是哈三联，截至5月31日最新股东户数为40260户，较5月20日下降25.74 ...